New Insights into Nephrogenic Systemic Fibrosis
Open Access
- 1 October 2007
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 18 (10), 2636-2643
- https://doi.org/10.1681/asn.2007060645
Abstract
Nephrogenic systemic fibrosis is a new disorder reported almost exclusively in patients who have renal insufficiency and are exposed to contrast media formulated with gadolinium. High morbidity and mortality are associated with this severely disabling and painful condition. The acute phase begins upon exposure to gadolinium contrast media, characterized by a systemic inflammatory response involving iron mobilization, and then as a progressive, chronic phase in which fibrosis develops. Proposed is a unifying model of cumulative risk factors in which the interplay of systemic inflammation and stimulated hematopoietic environment associated with hyperparathyroidism and erythropoietin may tie to a common pathogenic mechanism of fibrogenesis. Because there are no uniformly effective interventions to treat nephrogenic systemic fibrosis other than successful renal transplantation, prevention by avoiding gadolinium contrast media in patients with chronic kidney disease is vital. On the basis of suspected pathogenesis, it is also reasonable to limit erythropoietin and iron therapy to dosages ensuring recommended targets and adequately control hyperparathyroidism. Herein is reviewed what is currently known about this subject.Keywords
This publication has 69 references indexed in Scilit:
- Nephrogenic Systemic Fibrosis, Gadolinium, and Iron MobilizationThe New England Journal of Medicine, 2007
- Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosisJournal of the American Academy of Dermatology, 2007
- Targeting the stem cell niche: squeezing blood from bonesBone Marrow Transplantation, 2007
- Infectious disease, the innate immune response, and fibrosisJCI Insight, 2007
- Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organJCI Insight, 2007
- Common and unique mechanisms regulate fibrosis in various fibroproliferative diseasesJCI Insight, 2007
- Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamideEuropean Radiology, 2006
- Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activitiesProceedings of the National Academy of Sciences of the United States of America, 2006
- RENAL RESEARCH INSTITUTE SYMPOSITUM: Characteristics and Effects of Inflammation in End‐Stage Renal DiseaseSeminars in Dialysis, 2003
- Low Doses of EPO Activate MAP Kinases but Not JAK2–STAT5 in Rat Vascular Smooth Muscle CellsBiochemical and Biophysical Research Communications, 2001